Drug Trial Radar · NCT05891366
Single Ascending Dose Study of WAL0921 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
May 31, 2023
Primary completion
Jan 9, 2024
Study completion Jan 9, 2024
Sponsor
- Lead sponsor
- Walden BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Jun 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of WAL0921 in healthy subjects.
Conditions
- Healthy
Interventions
WAL0921Drug
Investigational product WAL0921
PlaceboDrug
Placebo product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse eventsTime frame: Day 1 to Day 64
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Pharmacology Unit
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.